{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Inaba H"],"funding":["NCI NIH HHS"],"pagination":["3625-32"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC3462046"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["30(29)"],"pubmed_abstract":["<h4>Purpose</h4>In acute myeloid leukemia (AML), initial treatment response by morphologic analysis of bone marrow predicts long-term outcome. Response can now be assessed by minimal residual disease (MRD) monitoring with flow cytometry or polymerase chain reaction (PCR). We determined the relation among the results of these approaches and their prognostic value.<h4>Patients and methods</h4>In the multicenter AML02 study, follow-up bone marrow samples from 203 children and adolescents with newly diagnosed AML were examined by flow cytometry (n = 1,514), morphology (n = 1,382), and PCR amplification of fusion transcripts (n = 508). Results were correlated with treatment outcome.<h4>Results</h4>Among 1,215 samples with less than 5% leukemic myeloblasts by morphology, 100 (8.2%) were MRD posi"],"journal":["Journal of clinical oncology : official journal of the American Society of Clinical Oncology"],"pubmed_title":["Comparative analysis of different approaches to measure treatment response in acute myeloid leukemia."],"pmcid":["PMC3462046"],"funding_grant_id":["R25 CA23944","P30 CA021765","R25 CA023944","R01 CA115422","R01CA115422","P30CA21765"],"pubmed_authors":["Pounds SB","Inaba H","Ribeiro RC","Degar B","Pui CH","Jacobsen J","Coustan-Smith E","Shurtleff SA","Wang KY","Rubnitz JE","Cao X","Dahl GV","Onciu M","Raimondi SC","Downing JR","Leung W","Taub JW","Campana D","Bowman WP"],"additional_accession":[]},"is_claimable":false,"name":"Comparative analysis of different approaches to measure treatment response in acute myeloid leukemia.","description":"<h4>Purpose</h4>In acute myeloid leukemia (AML), initial treatment response by morphologic analysis of bone marrow predicts long-term outcome. Response can now be assessed by minimal residual disease (MRD) monitoring with flow cytometry or polymerase chain reaction (PCR). We determined the relation among the results of these approaches and their prognostic value.<h4>Patients and methods</h4>In the multicenter AML02 study, follow-up bone marrow samples from 203 children and adolescents with newly diagnosed AML were examined by flow cytometry (n = 1,514), morphology (n = 1,382), and PCR amplification of fusion transcripts (n = 508). Results were correlated with treatment outcome.<h4>Results</h4>Among 1,215 samples with less than 5% leukemic myeloblasts by morphology, 100 (8.2%) were MRD posi","dates":{"release":"2012-01-01T00:00:00Z","publication":"2012 Oct","modification":"2026-04-29T19:46:03.935Z","creation":"2019-03-27T00:58:35Z"},"accession":"S-EPMC3462046","cross_references":{"pubmed":["22965955"],"doi":["10.1200/JCO.2011.41.5323","10.1200/jco.2011.41.5323"]}}